You know how Week 1 immediately divided the user base into two factions, those who regarded opening weekend as its own ...

A host of young receivers, including rookies Ja’Kobi Lane and Elijah Sarratt, have an opportunity to earn consistent playing ...

But right now, is one recent disturbing trend bad news for Lilly in this key growth market? Let's find out. So, first, a bit of background on these pharma companies' portfolios. Novo sells semaglutide ...

When Laura Patnaude stepped into her wedding gown for her first fitting last month, she asked her seamstress, “How much ...

Consumers should be more circumspect when considering these telehealth sites. They might provide an easier or cheaper avenue ...

The popular obesity drugs are being cavalierly prescribed. It should be yet another wake-up call for regulators. Virtual clinics are popular with patients who have become frustrated by the often ...

GLP-1 medications have transformed the way doctors treat obesity in adults — but as demand grows, a new question is emerging: ...

But at this stage of Eli Lilly's crucial obesity-drug business, the greenest pastures are currently overseas.

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set as demand for obesity therapeutics keeps ...

A new report from Gallup shows Americans' use of GLP-1 drugs for weight loss has nearly quadrupled in the last two years.

And the conversation has moved well past "does it work." People are now asking a bigger question: if a huge chunk of the ...

The hospital said it would expect to save $19 million dollars each year, but staff are skeptical of the long-term costs.